# Ribociclib

## Kisqali 200mg

##### 臨採

| TAH Drug Code      | [**OKIS**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OKIS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Dosing             | 600 mg orally once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food. Coadminister KISQALI with letrozole 2.5 mg taken once daily throughout the 28-day cycle. Patients should take their dose of KISQALI and letrozole at approximately the same time each day, preferably in themorning.  Recommended Dose Modification for Adverse Reactions: - Starting dose: 600 mg/day (three 200 mg tablets) - 1st dose reduction: 400 mg/day (two 200 mg tablets) - 2nd dose reduction: 200 mg/day (one 200 mg tablet) If further dose reduction below 200 mg/day is required, discontinue the treatment.                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Known hypersensitivity to Ribociclib succinate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | >10%: Cardiovascular: Peripheral edema (12%) Central nervous system: Fatigue (37%), headache (22%), insomnia (12%) Dermatologic: Alopecia (33%), skin rash (17%), pruritus (14%) Endocrine & metabolic: Decreased serum potassium (11%) Gastrointestinal: Nausea (52%), diarrhea (35%), vomiting (29%), constipation (25%), decreased appetite (19%), stomatitis (12%), abdominal pain (11%) Genitourinary: Urinary tract infection (11%) Hematologic & oncologic: Neutropenia (75%; grade 3: 50%; grade 4: 10%), leukopenia (33%; grade 3: 20%; grade 4: 1%), decreased platelet count (29%; grade 3: 1%), anemia (18%; grade 4: <1%), abnormal phosphorus levels (decreased; 13%; grade 3: 5%; grade 4: 1%), lymphocytopenia (11%; grade 3: 6%; grade 4: 1%) Hepatic: Increased serum ALT (<46%), increased serum AST (<44%), increased serum bilirubin (18%) Neuromuscular & skeletal: Back pain (20%) Renal: Increased serum creatinine (20%) Respiratory: Dyspnea (12%) Miscellaneous: Fever (13%) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

